| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/11/2001 | WO2001002440A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 01/11/2001 | WO2001002426A1 A substantially crystalline form of melagatran |
| 01/11/2001 | WO2001002422A1 PROCESS FOR OBTAINING 17β-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS |
| 01/11/2001 | WO2001002411A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE |
| 01/11/2001 | WO2001002409A1 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists |
| 01/11/2001 | WO2001002408A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002400A1 Fused imidazole compounds and remedies for diabetes mellitus |
| 01/11/2001 | WO2001002399A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | WO2001002398A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 01/11/2001 | WO2001002386A1 SELECTIVE M2 MUSCARINIC RECEPTOR ANTAGONISTS HAVING 5H-DIBENZ[b,f]AZEPINE STRUCTURE |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002380A1 Antipsychotic cyclic n-aralkyl amines |
| 01/11/2001 | WO2001002377A1 Telomerase inhibitors and methods of their use |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002360A1 Process for preparing amlodipine benzenesulphonate |
| 01/11/2001 | WO2001002349A1 Phenyl sulfamate derivatives |
| 01/11/2001 | WO2001002344A1 Aminobenzoic acid derivatives |
| 01/11/2001 | WO2001002018A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 01/11/2001 | WO2001002002A1 Stabilized pharmaceutical composition in lyophilized form |
| 01/11/2001 | WO2001001998A2 Treatment of endometriosis with antileukoprotease |
| 01/11/2001 | WO2001001987A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001974A2 Naaladase inhibitors in anxiety and memory disorders |
| 01/11/2001 | WO2001001973A2 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | WO2001001972A2 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001958A1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 01/11/2001 | WO2001001947A1 Cosmetic skin care compositions containing cumic alcohol |
| 01/11/2001 | WO2001001940A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 01/11/2001 | WO2001001939A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 01/11/2001 | WO2001001932A2 Oligosaccharide aldonic acids and their topical use |
| 01/11/2001 | WO2001001749A2 FVIIa ANTAGONISTS |
| 01/11/2001 | WO2001001748A2 Peptide compounds that bind her2 |
| 01/11/2001 | WO2000062800A3 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 01/11/2001 | WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds |
| 01/11/2001 | WO2000061167A3 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000059485A3 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 01/11/2001 | WO2000058466A3 Protease resistant flint analogs |
| 01/11/2001 | WO2000057868A3 Use of carbamamic acid derivatives for the treatment of viral infections |
| 01/11/2001 | WO2000056345A3 Methods for limiting scar and adhesion formation |
| 01/11/2001 | WO2000053596A3 Imidazole compounds as histamine h3 ligands |
| 01/11/2001 | WO2000053169A8 Method of inhibiting a chaperone protein |
| 01/11/2001 | WO2000051546A3 Bupropion metabolites and methods of their synthesis and use |
| 01/11/2001 | WO2000039278A8 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 01/11/2001 | DE19932315A1 Benzoylpyridazine Benzoylpyridazine |
| 01/11/2001 | DE19930177A1 Intermolekular assoziierende Verbindungen und diese umfassende Aggregate Inter-molecular compounds and associating this comprehensive aggregates |
| 01/11/2001 | DE19929993A1 New creatine alpha-ketoglutarate compounds, having synergistic activity e.g. in improving sporting strength and endurance, eliminating blood ammonia or treating liver diseases |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | CA2643231A1 Norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2378467A1 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2377931A1 Novel mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | CA2377795A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | CA2377780A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 01/11/2001 | CA2377731A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 01/11/2001 | CA2377684A1 Screening method |
| 01/11/2001 | CA2376944A1 A substantially crystalline form of melagatran |
| 01/11/2001 | CA2376681A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/11/2001 | CA2376673A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | CA2376657A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | CA2376553A1 Aminobenzoic acid derivatives |
| 01/11/2001 | CA2373883A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | CA2373881A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | CA2373844A1 Cosmetic skin care compositions containing cumic alcohol |
| 01/11/2001 | CA2373735A1 Fviia antagonists |
| 01/11/2001 | CA2373352A1 Adenoviral vectors for treating disease |
| 01/11/2001 | CA2342864A1 Process for obtaining 17.beta.-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids |
| 01/11/2001 | CA2341253A1 Telomerase inhibitors and methods of their use |
| 01/10/2001 | EP1067136A1 New peptide derivatives |
| 01/10/2001 | EP1067130A1 Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient |
| 01/10/2001 | EP1066854A2 Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds |
| 01/10/2001 | EP1066835A1 Composition containing the pepino extracts for lowering the concentration of alcohol in the blood and method for producing the same |
| 01/10/2001 | EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/10/2001 | EP1066821A1 Topical cosmetic product containing benzaldoxims |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066316A1 Cinnamic acid derivatives having cell adhesion modulating activity |
| 01/10/2001 | EP1066315A1 Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
| 01/10/2001 | EP1066310A1 Neokine protein and nucleic acid molecules and uses therefor |
| 01/10/2001 | EP1066307A1 3',3'-n-bis-substituted macrolide lhrh antagonists |
| 01/10/2001 | EP1066304A1 Macrolide lhrh antagonists |
| 01/10/2001 | EP1066297A1 Phosphinic acid derivatives |
| 01/10/2001 | EP1066293A2 New porphyrins and their use |
| 01/10/2001 | EP1066292A1 Metallocorrinoids as biologically compatible carriers of pharmacological agents |
| 01/10/2001 | EP1066290A1 PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR |
| 01/10/2001 | EP1066288A2 Novel compounds |
| 01/10/2001 | EP1066287A1 Azatricyclic compounds |
| 01/10/2001 | EP1066286A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 01/10/2001 | EP1066285A1 Antagonists of gonadotropin releasing hormone |
| 01/10/2001 | EP1066283A2 Substituted indolealkanoic acids |
| 01/10/2001 | EP1066279A1 Imidazolone anorectic agents: ii. phenyl derivatives |
| 01/10/2001 | EP1066278A1 Imidazolone anorectic agents: iii. heteroaryl derivatives |
| 01/10/2001 | EP1066273A1 Metalloproteinase inhibitors |